mCRPC Clinical Trial - Continuation Protocol for ZEN003694 in Patients

Status Enrolling by invitation

Clinical Trial Summary

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Clinical Trial Description

This is an open label, non-randomized, single-arm continuation protocol study using ZEN003694. Patients who have completed participation in their original ("parent") ZEN003694 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in the continuation protocol. The patient must have been enrolled in a Zenith Epigenetics sponsored ZEN003694 therapeutic study to be eligible for participation in this continuation protocol. ;

Study Design

Related Conditions & MeSH terms

mCRPC

Clinical Trial Details

NCT number	NCT04145375
Study type	Interventional
Source	Zenith Epigenetics
Contact
Status	Enrolling by invitation
Phase	Phase 1/Phase 2
Start date	November 12, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05383079` - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer	Phase 1/Phase 2
Recruiting	`NCT06056791` - Study of INKmune in Patients With mCRPC (CaRe Prostate)	Phase 1/Phase 2
Recruiting	`NCT04729114` - Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT02266745` - A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts	Phase 2
Recruiting	`NCT05413850` - Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection	Phase 1/Phase 2
Recruiting	`NCT05340374` - Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer	Phase 1/Phase 2
Completed	`NCT01818986` - Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)	Phase 2
Not yet recruiting	`NCT04822961` - Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	Phase 2
Active, not recruiting	`NCT03395197` - Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC	Phase 3
Recruiting	`NCT05547061` - A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy	Phase 1/Phase 2
Recruiting	`NCT03851640` - A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).	Phase 3